文献速递皮肤感染银屑病与炎症性皮肤病

阿普司特治疗慢性难治性麻风结节性红斑:两例报告

Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases.
PubMed 文献 · Br J Dermatol · 2019-09-05

本文报告两例多药治疗效果不佳的慢性麻风结节性红斑(ENL)患者,均在接受阿普司特后获得显著临床改善且无不良反应。作者据此提出阿普司特可能成为慢性ENL的新型治疗选择。

要点

  • 慢性ENL常用糖皮质激素、沙利度胺等免疫抑制剂,但并非普遍有效且毒性风险明显。
  • 两例难治性慢性ENL患者使用阿普司特后临床显著改善,未观察到不良反应。
  • 阿普司特作为口服磷酸二酯酶-4抑制剂,可能为慢性ENL提供新的治疗选项。

核心结论

  • 阿普司特可能对慢性麻风结节性红斑有效,两例患者均获显著临床改善且无不良反应。

研究设计与样本

  • 病例报告,共纳入两例多药治疗效果不佳的慢性麻风结节性红斑患者。

主要发现

  • 两例慢性ENL患者在此前多种治疗药物下控制不佳,使用阿普司特后均出现显著临床改善,且未出现任何不良反应。

临床怎么用

  • 对多种免疫抑制剂控制不佳的慢性ENL患者,可考虑阿普司特作为潜在治疗选择,但需更多研究验证。

局限性

  • 仅为两例病例报告,样本量小,缺乏对照,结论需更大规模研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Erythema nodosum leprosum (ENL) is a severe immune reaction commonly encountered as a complication in patients with multibacillary leprosy. Management of chronic ENL in leprosy is challenging and necessitates the use of systemic immunosuppressants, including corticosteroids and thalidomide. No single drug is universally effective and most current therapeutic agents carry a significant risk of systemic toxicity. Apremilast is an orally effective phosphodiesterase-4 inhibitor with a potent immunomodulatory action and is clinically effective in inflammatory conditions like chronic plaque psoriasis. We report two patients with poorly controlled chronic ENL, despite the use of multiple therapeutic agents. Both patients demonstrated significant clinical improvement with apremilast, without any adverse effects, thereby suggesting its potential as a novel therapeutic option in chronic ENL. What's already known about this topic? Erythema nodosum leprosum (ENL) is an immune-mediated reaction in patients with multibacillary leprosy, with chronicity and recurrences frequently reported. Management of chronic ENL requires systemic immunosuppressants like corticosteroids, which may not be universally effective and carry a risk of serious toxicity. Apremilast is an oral immunomodulator with good efficacy in inflammatory conditions like chronic plaque psoriasis. What does this study? Apremilast may be an effective therapeutic agent in patients with chronic ENL.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Narang T, Kaushik A, Dogra S, et al. Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases. Br J Dermatol. 2019. PMID: 31218666. doi:10.1111/bjd.18233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。